Finance

Syncona enters kidney disease space with gene therapy newco Purespring

Firm launches sixth gene therapy start-up with £45M to reach clinic

Syncona’s Purespring pushes gene therapy beyond monogenic disorders in kidney diseases.

The launch of Purespring Therapeutics marks the next phase of Syncona’s strategy in moving gene therapy from targeting rare monogenic diseases to more